Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

ClinicalTrials.gov ID: NCT01507831

Public ClinicalTrials.gov record NCT01507831. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Long-term Safety and Tolerability of SAR236553 (REGN727) in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy: A Randomized, Double-Blind, Placebo-Controlled Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9). Primary Objective of the study: To evaluate the long-term safety and tolerability of alirocumab in high cardiovascular risk participants with hypercholesterolemia not adequately controlled with their current lipid modifying therapy (LMT). Secondary Objectives: * To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 24 weeks of treatment in comparison with placebo. * To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time points. * To evaluate the effects of alirocumab on other lipid parameters.

Study identification

NCT ID
NCT01507831
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sanofi
Industry
Enrollment
2,341 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2012 (Type not available)
Primary completion
Nov 2014 (Actual)
Completion
Nov 2014 (Actual)
Last update posted
Dec 22, 2015

2012 – 2014

United States locations

U.S. sites
115
U.S. states
28
U.S. cities
93
Facility City State ZIP Site status
Investigational Site Number 840159 Huntsville Alabama 35801 —
Investigational Site Number 840028 Gilbert Arizona 85295 —
Investigational Site Number 840035 Sierra Vista Arizona 85635 —
Investigational Site Number 840052 Tempe Arizona 85282 —
Investigational Site Number 840065 Tempe Arizona 85282 —
Investigational Site Number 840079 Tempe Arizona 85282 —
Investigational Site Number 840094 Tempe Arizona 85282 —
Investigational Site Number 840103 Tucson Arizona 85741-3565 —
Investigational Site Number 840209 Beverly Hills California 90210 —
Investigational Site Number 840194 Beverly Hills California 90211 —
Investigational Site Number 840207 Fresno California 93720 —
Investigational Site Number 840101 Lincoln California 95648 —
Investigational Site Number 840076 Long Beach California 90807 —
Investigational Site Number 840214 Pasadena California 91105 —
Investigational Site Number 840045 Sacramento California 95842 —
Investigational Site Number 840163 Santa Rosa California 95405 —
Investigational Site Number 840086 Colorado Springs Colorado 80906 —
Investigational Site Number 840077 Golden Colorado 80401 —
Investigational Site Number 840224 Bridgeport Connecticut 06610 —
Investigational Site Number 840134 Guilford Connecticut 06437 —
Investigational Site Number 840246 Hartford Connecticut 06102 —
Investigational Site Number 840055 Stamford Connecticut 06905 —
Investigational Site Number 840091 Stamford Connecticut 06905 —
Investigational Site Number 840150 Atlantis Florida 33462 —
Investigational Site Number 840020 Bradenton Florida 34208 —
Investigational Site Number 840041 Brandon Florida 33511 —
Investigational Site Number 840184 Clearwater Florida 33756 —
Investigational Site Number 840242 Clearwater Florida 33756 —
Investigational Site Number 840039 Clearwater Florida 33765 —
Investigational Site Number 840182 Crystal River Florida 34429 —
Investigational Site Number 840002 Daytona Beach Florida 32117 —
Investigational Site Number 840166 Daytona Beach Florida 32117 —
Investigational Site Number 840167 Fleming Island Florida 32003 —
Investigational Site Number 840090 Fort Lauderdale Florida 33308 —
Investigational Site Number 840018 Fort Lauderdale Florida 33309 —
Investigational Site Number 840153 Jacksonville Florida 32204 —
Investigational Site Number 840181 Jacksonville Florida 32205 —
Investigational Site Number 840152 Jacksonville Florida 32216 —
Investigational Site Number 840154 Lake Mary Florida 32746 —
Investigational Site Number 840059 Largo Florida 33773 —
Investigational Site Number 840221 Miami Florida 33176 —
Investigational Site Number 840021 New Port Richey Florida 34652 —
Investigational Site Number 840122 New Smyrna Beach Florida 32169 —
Investigational Site Number 840151 Ocala Florida 34471 —
Investigational Site Number 840108 Ormond Beach Florida 32174 —
Investigational Site Number 840067 Palm Harbor Florida 34684 —
Investigational Site Number 840006 Pembroke Pines Florida 33026 —
Investigational Site Number 840168 Ponte Vedra Florida 32081 —
Investigational Site Number 840164 Sarasota Florida 34239 —
Investigational Site Number 840175 Sarasota Florida 34239 —
Investigational Site Number 840001 St. Petersburg Florida — —
Investigational Site Number 840003 St. Petersburg Florida — —
Investigational Site Number 840036 West Palm Beach Florida 33401 —
Investigational Site Number 840117 Cumming Georgia 30041 —
Investigational Site Number 840110 Roswell Georgia 30076 —
Investigational Site Number 840026 Savannah Georgia 31405 —
Investigational Site Number 840075 Meridian Idaho 83646 —
Investigational Site Number 840027 Evansville Indiana 47714 —
Investigational Site Number 840093 Indianapolis Indiana 46260 —
Investigational Site Number 840222 Iowa City Iowa 52242 —
Investigational Site Number 840165 West Des Moines Iowa 50266 —
Investigational Site Number 840200 Kansas City Kansas 66160-7321 —
Investigational Site Number 840040 Wichita Kansas 67203 —
Investigational Site Number 840061 Wichita Kansas 67205 —
Investigational Site Number 840032 Wichita Kansas 67207 —
Investigational Site Number 840084 Wichita Kansas 67207 —
Investigational Site Number 840244 Biddeford Maine 04005 —
Investigational Site Number 840158 Framingham Maine 01702 —
Investigational Site Number 840193 Novi Michigan 48374 —
Investigational Site Number 840162 Saginaw Michigan 48604 —
Investigational Site Number 840033 St Louis Missouri 63117 —
Investigational Site Number 840113 St Louis Missouri 63131 —
Investigational Site Number 840095 Henderson Nevada 89052 —
Investigational Site Number 840096 Henderson Nevada 89052 —
Investigational Site Number 840022 Edison New Jersey 08817 —
Investigational Site Number 840011 Hillsborough New Jersey 08844 —
Investigational Site Number 840049 Trenton New Jersey 08611 —
Investigational Site Number 840097 Bronxville New York 10708 —
Investigational Site Number 840129 Brooklyn New York 11215 —
Investigational Site Number 840160 Poughkeepsie New York 12601 —
Investigational Site Number 840217 Asheville North Carolina 28803 —
Investigational Site Number 840023 Charlotte North Carolina 28211 —
Investigational Site Number 840083 Greensboro North Carolina 27408 —
Investigational Site Number 840104 Raleigh North Carolina 27609 —
Investigational Site Number 840068 Cincinnati Ohio 45236 —
Investigational Site Number 840007 Dayton Ohio 45406 —
Investigational Site Number 840013 Marion Ohio 43302 —
Investigational Site Number 840161 Mentor Ohio 44060 —
Investigational Site Number 840005 Tulsa Oklahoma 74136 —
Investigational Site Number 840170 Beaver Pennsylvania 15009 —
Investigational Site Number 840180 Camp Hill Pennsylvania 17011 —
Investigational Site Number 840004 Duncansville Pennsylvania 16635 —
Investigational Site Number 840046 Jersey Shore Pennsylvania 17740 —
Investigational Site Number 840155 Phoenixville Pennsylvania 19460 —
Investigational Site Number 840177 Scranton Pennsylvania 18508 —
Investigational Site Number 840202 Wyomissing Pennsylvania 19610 —
Investigational Site Number 840073 Charleston South Carolina 29485 —
Investigational Site Number 840087 Greenville South Carolina 29615 —
Investigational Site Number 840074 Simpsonville South Carolina 29681 —
Investigational Site Number 840105 Varnville South Carolina 29944 —
Investigational Site Number 840190 Knoxville Tennessee 37917 —
Investigational Site Number 840092 Dallas Texas 75216 —
Investigational Site Number 840212 Dallas Texas 75226 —
Investigational Site Number 840058 Fort Worth Texas 76104 —
Investigational Site Number 840149 Fort Worth Texas 76104 —
Investigational Site Number 840070 Fort Worth Texas 76117 —
Investigational Site Number 840038 Houston Texas 77024 —
Investigational Site Number 840047 Houston Texas 77074 —
Investigational Site Number 840053 Plano Texas 75023 —
Investigational Site Number 840072 Sugar Land Texas 77479 —
Investigational Site Number 840241 Tyler Texas 75701 —
Investigational Site Number 840031 Salt Lake City Utah 84107 —
Investigational Site Number 840204 Chesapeake Virginia 23320 —
Investigational Site Number 840120 Spokane Washington 99204 —
Investigational Site Number 840111 Milwaukee Wisconsin 53209-0996 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 205 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01507831, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 22, 2015 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01507831 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →